To test the utility of 3D liver microtissues for compound de-risking, we investigated the hypothesis that species differences in thyroxine metabolism by UGT could underlie differences in susceptibility to thyroid carcinogenesis in rats and humans. Using bioinformatic analysis of microarray and proteomics data derived from PB treated rat and human liver 3D microtissues, we found a differential effect in the induction of UGT isoforms between the two species, supporting a role for 3D microtissues in the investigation of adverse outcome pathways (AOPs) and discovery safety assessment.
Published in Toxicology Reports (Volume 8, 2021, Pages 155-161), the paper describes how our proprietary SpheroMatrices microTMA technology can be used to understand toxicity risk in discovery safety screening.
enquiries to: simonplummer@micromatrices.com
Histology and Microphysiological systems (MPS)
In vitro 3D models are increasingly integral to drug discovery and drug development programs with many commercial safety…
Meet us in San Diego at SOT 2022
We look forward to re-connecting with clients/colleagues at the first on-site SOT in two years, held this year…
Transcriptomics with SpheroMatrices microTMA
The addition of a spatially defined overlay of transcriptomics to cytotoxicity/histological findings, or biomarker expression/localization image data, adds…
on an interactive, step by step basis. Collaborations can begin with pilot projects which can then be scaled up to larger research programs, according to your requirements.